Skip to main content
. 2017 Dec 22;11(3):261–266. doi: 10.1111/cts.12532

Figure 3.

Figure 3

Kaplan–Meier curves showing progression‐free survival (PFS) in patients with relapsed or refractory multiple myeloma receiving elotuzumab plus lenalidomide and dexamethasone (“Elotuzumab”) or lenalidomide and dexamethasone (“Control”). Figure from Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621–631. ©2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.